Allen Shyu

Partner

Areas of Focus

Allen Shyu

Partner

ashyu@akingump.com

Areas of Focus

Save as PDF

Share This Biography

Biography
Allen Shyu is a registered foreign lawyer in Akin Gump's Hong Kong office.
  • Visiting Professor and Master Supervisor of China University of Political Science and Law, School of Juris Master.
  • For nearly 20 years, has advised on sophisticated capital markets transactions and cross-border mergers and acquisitions.
  • Significant experience counseling Chinese companies on the United States securities aspects of global public offerings, including initial public offerings and Rule 144A offerings.
  • Represents investment banks, securities houses and venture capital and private equity firms.

Allen Shyu has nearly two decades of experience representing companies from mainland China, Hong Kong and Taiwan in their U.S. and global securities offerings and cross-border mergers and acquisitions. His corporate practice also encompasses advising investment banks, securities houses and venture capital and private equity firms.

In recent years, Allen has worked on numerous transactions for mid- and large-sized Chinese public companies, handling the U.S. securities aspects of global public offerings, including initial public offerings and Rule 144A offerings. Additionally, he counsels on equity-linked securities (including convertible bonds and depository receipts) for companies active throughout Asia.

Before joining Akin, Allen worked in and led his previous firm’s U.S. securities group, focusing and emphasizing on due disclosure and legal compliance under U.S. securities laws and regulations for issuers who sought for Hong Kong listing, including but not limited to the issuance of Rule 10b-5 disclosure letter. Issuers and world’s leading bankers found the rigorous yet commercial approaches adopted by Allen and backed up by his ample experience helpful and reliable.

A native of Taiwan, Allen provides regular counsel to Taiwanese companies issuing equity and equity-linked securities. He also advises on venture capital and private equity transactions for emerging companies in that market.

Representative Work

Allen’s experience includes advising:

  • the founders of a Delaware limited liability company, which specializes in creating health economic models that bridge the gap between market access and commercial teams, in the selling of membership interests to a Delaware corporation, a special purpose acquisition company formed for the purpose of entering into a combination with one or more businesses or entities.
  • $130 million global offering and Hong Kong listing of Zhejiang New Century Hotel Management Co., Ltd. underwritten by China Galaxy, BOCOM and Morgan Stanley (sponsor representation).*
  • $35.6 million global offering and Hong Kong listing of Byleasing Holdings Limited underwritten by Changjiang Corporate Finance (sponsor representation).*
  • $50 million global offering and Hong Kong listing of Jiangsu Innovative Ecological New Materials Limited underwritten by Orient and Guotai Junan (issuer representation).*
  • $38.7 million global offering and Hong Kong listing of Quanzhou Huixin Micro-credit Co., Ltd. underwritten by Changjiang Corporate Finance (issuer representation).*
  • 100 percent share acquisition of GNB Corporation on behalf of Kinglai Hygienic Materials Co., Ltd.*
  • $400 million senior notes due in 2019 with an annual interest of 7.8 percent of Evergrande Real Estate Group Limited as the U.S. Special Counsel for Industrial Bank Hong Kong Branch.*
  • $1 billion global offering and Hong Kong listing of Bank of Jinzhou Co., Ltd. underwritten by CMB (issuer representation).
  • $99.31 million convertible bonds (ECBs) on SGX and global depositary receipts (GDR) on the main board of HKEx on behalf of Wisdom Marine Lines S.A.*
  • $50 million global offering and Hong Kong listing of Zuoli Kechuang Micro-finance Company Limited underwritten by China Galaxy (sponsor representation).*
  • $450 million global offering and Hong Kong listing of YuanShengTai Dairy Farm Limited with a Rule 144A/Regulation S placement to global investors underwritten by Credit Suisse, Macquarie, and CSCI (issuer representation).*
  • $83 million global offering and Hong Kong listing of Hosa International Limited with a Rule 144A/Regulation S placement to global investors underwritten by Merrill Lynch (issuer representation).*
  • $384 million global offering and Hong Kong listing of Billion Industrial Holdings Limited with a Rule 144A/Regulation S placement to global investors underwritten by UBS, CCB, and Merrill Lynch (issuer representation).*
  • $213 million global offering and Hong Kong listing of Biostime International Holdings Limited with a Rule 144A/Regulation S placement to global investors underwritten by HSBC (issuer representation).*
  • $348 million global offering and Hong Kong listing of Yashili International Holdings Ltd. with a Rule 144A/Regulation S placement to global investors underwritten by Merrill Lynch, UBS, and Citic (issuer representation).*
  • $1.29 billion global offering and Hong Kong listing of China Pharmaceutical Group with a Rule 144A/Regulation S placement to global investors underwritten by CICC, UBS, Morgan Stanley Citi and Deutsche Bank (issuer representation).*
  • $610 million global offering and Hong Kong listing of China South Locomotive and Rolling Stock Corporation Limited with a Rule 144A/Regulation S placement to global investors underwritten by CICC and Macquarie (issuer representation).*
  • $2.6 billion global offering and Hong Kong listing of China Railway Construction Corporation with a Rule 144A/Regulation S placement to global investors underwritten by Citi, Macquarie and Citic (issuer representation).*
  • $1.95 billion global offering and Hong Kong listing of China Coal Energy Company Limited with a Rule 144A/Regulation S placement to global investors underwritten by CICC, Citi and Morgan Stanley (issuer representation).*
  • $310 million global offering and Hong Kong listing by Jin Jiang International Co., Ltd. with a Rule 144A/Regulation S placement to global investors underwritten by BNP and UBS (issuer representation).*
  • $390 million global offering and Hong Kong listing of China Blue Chemical Co., Ltd. with a Rule 144A/Regulation S placement to global investors underwritten by UBS and JPMorgan (issuer representation).*

*Includes work completed prior to Akin Gump Strauss Hauer & Feld LLP.

Languages
  • English

  • Mandarin

  • Taiwanese

Education
  • J.D., University of Detroit Mercy School of Law, 1997

  • LL.B., National Taiwan University, 1990

  • M.A., University of Detroit Mercy, 1994

Bar Admissions
  • Illinois

  • Registered Foreign Lawyer in Hong Kong

Recognitions
  • Recognized in Capital Markets Law (International Firms), The Best Lawyers in China.

Insights and Achievements

          Related Content

          People

          Distinguished by our areas of focus, as a cohesive and integrated firm, we are defined by the caliber of our work, the responsiveness of our service and a culture that is rooted in collaboration and forward-thinking.

          We Also Recommend

          Loading...
          Loading...
          Loading...
          Loading...